此外，于2025年9月25日，CPL(该公司全资附属公司)及MSL(卖方全资拥有)订立出售协议。根据出售协 议，MSL已有条件同意收购及CPL已有条件同意出售或促使销售创升信贷及创升管理的全部已发行股 本，总代价为5820万万港元(可予调整)。出售完成须待达成若干先决条件方告作实。 公司已向联交所申请批准股份由2025年10月13日上午9时正起于联交所恢复买卖。 根据收购守则规则26.1，紧随完成后，要约人将须就所有已发行股份(要约人及其一致行动人士已拥有 或同意将予收购者除外)作出强制性无条件现金要约。每股要约股份现金6.00港元，较股份在联交所所 报于2025年9月25日(即最后交易日)的收市价每股5.66港元溢价约6.0%。要约将涉及1500万股股份。根据 要约价每股要约股份6.00港元计算，要约代价将为9000万港元(假设悉数接纳要约)。 创升控股(02680)及要约人王庭发先生联合公布，于2025年9月25日(交易时段后)，要约人拟向公司董事 会主席、执行董事钟志文先生(卖方)收购110股销售股份，相当于买卖协议日期百阳的全部已发行股 本，总代价为2.7亿港元。于本联合公告日期，要约人已向卖方支付按 ...

来源：智通财经网 华康生物医学(08622)及要约人Anselme Limited联合公布，于2025年10月9日，要约人(作为买方)与卖方 李景杨(作为卖方)订立买卖协议，卖方有条件同意出售，而要约人有条件同意收购销售股份(即1.387亿 股股份)的全部法定及实益所有权及权益，占本公司于本联合公告日期已发行股本总额约27.71%，总代 价为1747.27万港元，相当于每股销售股份0.126港元。 紧接完成前，要约人直接及实益拥有1.21亿股股份，相当于本公司已发行股本总额约24.13%。紧随完成 后及于本联合公告日期，要约人、周博士及与彼等任何一方一致行动人士合共拥有2.59亿股股份的权 益，相当于本公司已发行股本总额约51.84%。除上述者外，概无要约人、周博士及与彼等任何一方一 致行动人士于任何其他股份及购股权拥有权益。根据收购守则规则26.1及13.5，要约人须提出强制性无 条件现金要约，以收购全部已发行股份(要约人及其一致行动人士已拥有或同意收购者除外);及注销全部 尚未行使购股权。 每股要约股份现金0.126港元，较股份于本联合公告日期在联交所所报收市价每股股份0.395港元折让约 68.10%。 ...

华康生物医学(08622)及要约人Anselme Limited联合公布，于2025年10月9日，要约人(作为买方)与卖方 李景杨(作为卖方)订立买卖协议，卖方有条件同意出售，而要约人有条件同意收购销售股份(即1.387亿 股股份)的全部法定及实益所有权及权益，占本公司于本联合公告日期已发行股本总额约27.71%，总代 价为1747.27万港元，相当于每股销售股份0.126港元。 紧接完成前，要约人直接及实益拥有1.21亿股股份，相当于本公司已发行股本总额约24.13%。紧随完成 后及于本联合公告日期，要约人、周博士及与彼等任何一方一致行动人士合共拥有2.59亿股股份的权 益，相当于本公司已发行股本总额约51.84%。除上述者外，概无要约人、周博士及与彼等任何一方一 致行动人士于任何其他股份及购股权拥有权益。根据收购守则规则26.1及13.5，要约人须提出强制性无 条件现金要约，以收购全部已发行股份(要约人及其一致行动人士已拥有或同意收购者除外);及注销全部 尚未行使购股权。 每股要约股份现金0.126港元，较股份于本联合公告日期在联交所所报收市价每股股份0.395港元折让约 68.10%。 于本联合公告日期 ...

Group 1 - Shanghai Zhiyuan Hengyue plans to acquire 37% of the shares of Shangwei New Materials at a price of 7.78 yuan per share, requiring a maximum total funding of 1.16 billion yuan [1] - The acquisition period is set for 30 calendar days, from September 29, 2025, to October 28, 2025 [1] - Zhiyuan Hengyue and Zhiyuan Xinchuan intend to acquire at least 63.62% and up to 66.99% of Shangwei New Materials' shares [2] Group 2 - Heng Rui Pharmaceutical has signed a licensing agreement for the innovative drug SHRA1811, receiving an upfront payment of 18 million dollars and is eligible for up to 1.093 billion dollars in milestone payments [3] - The agreement aims to expand the overseas market for SHRA1811 and enhance the company's innovative brand and overseas performance [3] Group 3 - Tian Shili's subsidiary has received approval for clinical trials of TSL2109 capsules, a dual-target small molecule inhibitor for advanced solid tumors, with no similar drugs currently in clinical trials [4] - The cumulative R&D investment in TSL2109 capsules by Jiangsu Diyi has reached 24.6251 million yuan [4] Group 4 - Wanhui High-tech expects a net profit of 340 million to 420 million yuan for the first three quarters, representing a year-on-year growth of 69.81% to 109.77% [5]

Group 1 - The company, Galaxy Magnetics (300127.SZ), is planning to acquire 100% equity of Sichuan Kyoto Longtai Technology Co., Ltd. through a combination of issuing shares and cash payment [1] - The company is also raising matching funds for this acquisition [1] - As a result of this announcement, the company's A-shares will be suspended from trading starting September 15, 2025 [1]

Group 1 - The core point of the article is that Intel has warned that the agreement with the Trump administration to acquire 9.9% of its shares may have negative effects on investors, employees, and other stakeholders [1] - Intel stated that the agreement could lead to the U.S. Department of Commerce acquiring up to 433.3 million shares, which would dilute the equity of existing shareholders [1] - The potential impact of Trump's shareholding may affect Intel's sales in overseas markets, as 76% of Intel's revenue came from outside the U.S. in the last fiscal year [2]

Group 1 - The seller, CLASSIFIED GP, has entered into a sale agreement with THAC Group (BVI) Limited to sell approximately 65.7% of its issued share capital, with completion expected on July 21, 2025 [1] - Following the completion, THAC Group and its concert parties will hold 36.6151 million shares, representing about 65.7% of the total issued share capital [1] - According to Rule 26.1 of the Takeovers Code, THAC Group is required to make a mandatory unconditional cash offer for all remaining issued shares at a price of HKD 1.318 per share, which is a premium of approximately 20.9% over the closing price of HKD 1.09 on June 30, 2025 [1] Group 2 - The directors of THAC Group include Mr. Guo Zhenkun, Mr. Chen Zhuoxi, and Ms. He Jiayi, with ownership stakes of 53%, 27%, and 10% respectively [2] - The company has applied to the Stock Exchange for the resumption of trading of its shares starting from 9:00 AM on July 23, 2025 [2]

Group 1 - The core viewpoint of the article is that Xinhua Investment Holdings Co., Ltd. is acquiring 51% of Xinhua Net Co., Ltd. through a non-compensatory transfer of shares, which does not require a public offer [1][10] - The acquisition involves the transfer of 264,679,740 shares from Xinhua News Agency to Xinhua Investment, which will result in Xinhua Investment holding a total of 318,779,610 shares, representing 61.42% of Xinhua Net's total share capital [9][10] - The legal opinion confirms that the acquisition complies with relevant regulations, specifically allowing for exemption from making a public offer due to the transfer occurring between entities under the same actual controller [9][12] Group 2 - Xinhua Investment is a limited liability company established on January 18, 2012, with a registered capital of 101 million yuan, and is wholly owned by Xinhua News Agency [4][5] - The consistent action relationship between Xinhua Investment and China Economic Information Society (the consistent action party) is established, with Xinhua Investment being the controlling shareholder of the latter [5][6] - The legal opinion states that both the acquirer and the consistent action party are legally established and do not fall under any prohibitive conditions for acquiring listed companies as per the regulations [7][12] Group 3 - The acquisition has undergone necessary approval procedures, and there are no substantial legal obstacles to its implementation [10][12] - The parties involved have fulfilled their disclosure obligations as required by the relevant regulations [11][12] - There have been no stock trading activities by the acquirer or its related parties in the six months prior to the issuance of the legal opinion, ensuring compliance with securities regulations [11][13]

Group 1 - Orkan IS ehf. has fulfilled certain conditions for acquiring 51.3% of Samkaup from Kaupfélag Suðurnesja, with a nominal value of ISK 221,386,719 [1] - Orkan has signed agreements with other shareholders to acquire their shares, leading to ownership of approximately 96% of Samkaup, and subsequently over 98.5% after reaching an agreement with another shareholder [2] - An agreement has been made with Íslandsbanki for an underwriting commitment of at least ISK 2 billion to strengthen Samkaup's financial position, valid for 180 days [3] Group 2 - All conditions for Orkan's purchase agreements with Samkaup shareholders have been met, pending approval from the Competition Authority regarding merger regulations [4]

Core Viewpoint - Disney will pay an additional $438.7 million to NBC Universal to acquire shares in Hulu, which will reduce Disney's net income attributable to the company in the third quarter [1] Financial Impact - The additional payment of $438.7 million will directly impact Disney's net income for the third quarter [1]